Vaccines against Chlamydia: approaches and progress.
Infections of the eye and genital tract with the bacterium Chlamydia trachomatis are a major cause of morbidity worldwide and are costly to treat. Development of a vaccine capable of protecting against infection or severe disease presents special challenges but would be the most effective long-term option for control of chlamydial disease. Progress has been made in understanding protective and pathological immune mechanisms in these infections, and a number of potential vaccine candidates have been developed.
Stagg
A J
AJ
Antigen Presentation Research Group, Imperial College School of Medicine at Northwick Park Hospital, Harrow, Middlesex, UK. a.stagg@ic.ac.uk
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000907:Antibodies, Bacterial / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines; D002690:Chlamydia Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D002692:Chlamydia trachomatis / Q000276:immunology*; D016207:Cytokines / Q000502:physiology; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007111:Immunity, Cellular; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D018272:Porins; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D018272:Porins; D014614:Vaccines, Synthetic; C071677:omp1 protein, Chlamydia trachomatis